Clinical Trials on HER2-low-expressing Breast Cancer
Total 11886 results
-
AstraZenecaDaiichi SankyoNot yet recruitingMetastatic Breast Cancer | HER2-positive Breast Cancer | Unresectable Breast Cancer | HER2-low Expressing Breast CancerCanada
-
Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo CompanyRecruitingMetastatic Breast Cancer | Unresectable Breast Cancer | HER2-low Expressing Breast CancerAustria, Belgium, Italy, Spain, France, Switzerland, Denmark, Norway, Sweden
-
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityJiangsu HengRui Medicine Co., Ltd.Active, not recruitingBreast Cancer | Neoadjuvant Therapy | Hormone Receptor-positive Breast Cancer | HER2-low-expressing Breast CancerChina
-
Fudan UniversityRecruiting
-
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityRecruitingHR Positive/HER2 Low Expression Metastatic Breast CancerChina
-
Jazz PharmaceuticalsALX Oncology Inc.Active, not recruitingHER2-expressing CancersUnited States
-
Galena Biopharma, Inc.CompletedBreast Cancer With Low to Intermediate HER2 ExpressionUnited States, United Kingdom, France, Israel, Germany, Canada, Russian Federation, Romania, Bulgaria, Czech Republic, Hungary, Poland, Ukraine
-
QuantumLeap Healthcare CollaborativeRecruitingSolid Tumor | Metastatic Cancer | Metastatic Breast Cancer | Triple Negative Breast Cancer | HER2-positive Breast Cancer | Solid Tumor, Adult | Solid Carcinoma | HER2-positive Metastatic Breast Cancer | Progesterone Receptor-positive Breast Cancer | HER2-negative Breast Cancer | Estrogen Receptor Positive... and other conditionsUnited States
-
Novartis PharmaceuticalsCompletedMetastatic Breast Cancer | HER2/Neu Over-expressing Locally Advanced Breast CancerChina, United States, France, Hungary, Turkey, Japan, Germany, Singapore, Italy, Poland, Spain, United Kingdom, Thailand, Israel, Australia, Belgium, Greece, Argentina, Czech Republic, Mexico, Slovakia
-
Amunix, a Sanofi CompanyMerck Sharp & Dohme LLCRecruitingLocally Advanced or Metastatic HER2-Expressing CancersAustralia, Spain, France, Portugal
-
Daiichi SankyoRecruitingBreast Cancer | Advanced Cancer | HER2-positive Breast Cancer | HER2-low Breast CancerChina
-
Daiichi SankyoCompletedHER2-negative Breast Cancer | HER2-low Breast Cancer | Hormone-receptor-positive Breast CancerUnited States
-
Mersana TherapeuticsRecruitingHER2-positive Breast Cancer | HER2-positive Gastric Cancer | HER2-positive Non-Small Cell Lung Cancer | HER2-positive Colorectal Cancer | HER2-positive Tumors | HER2 Low Breast CancerUnited States
-
Centre Oscar LambretTerminatedBreast Cancer | Metastasis | Sur-expressing Her2-neuFrance
-
Shanghai East HospitalRecruitingGastric Cancer | HER2-low-expressing Gastric CancerChina
-
QuantumLeap Healthcare CollaborativeByondis B.V.WithdrawnOvarian Cancer | Metastatic Cancer | Metastatic Breast Cancer | Bladder Cancer | Triple Negative Breast Cancer | HER2-positive Breast Cancer | Gastroesophageal Adenocarcinoma | Ovarian Carcinoma | HER2-positive Gastric Cancer | Metastatic Gastrointestinal Carcinoid Tumor | HER2-positive Metastatic Breast... and other conditionsUnited States
-
Gustave Roussy, Cancer Campus, Grand ParisDaiichi SankyoRecruitingAdvanced Breast Cancer | HER2-positive Metastatic Breast Cancer | Breast Cancer Metastatic | HER2 Low Breast CarcinomaFrance
-
Ichnos Sciences SAGlenmark Pharmaceuticals S.A.TerminatedHER2 Expressing Solid TumoursUnited States, Germany
-
Sichuan Baili Pharmaceutical Co., Ltd.RecruitingHer2-positive/Low-expression Urinary and Digestive Tract TumorsChina
-
H. Lee Moffitt Cancer Center and Research InstituteTerminatedBreast Cancer | Breast Cancer, Male | HER2-positive Breast Cancer | HER-2 Gene Amplification | Breast Cancer Female | HER2 Positive Breast Carcinoma | HER-2 Protein OverexpressionUnited States
-
Advaxis, Inc.CompletedHER2 Expressing Solid TumorsUnited States
-
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityNot yet recruitingBreast Cancer | HER2-low Breast CancerChina
-
Orum Therapeutics USA, Inc.RecruitingHER2-positive Breast Cancer | HER-2 Gene Amplification | HER2 Gene Mutation | HER-2 Protein OverexpressionUnited States
-
MedImmune LLCCompletedHER2 Expressing Breast or Gastric/Stomach CancersUnited States
-
Jiangsu HengRui Medicine Co., Ltd.RecruitingHER2-expressing Advanced Solid TumorsChina
-
Shengjing HospitalJiangsu HengRui Medicine Co., Ltd.Not yet recruitingER Positive/HER2 Low Breast CancerChina
-
Jiangsu HengRui Medicine Co., Ltd.Not yet recruitingHER2 Low Advanced or Metastatic Breast Cancer
-
National Cancer Institute (NCI)CompletedBreast Cancer | Breast Neoplasms | Adenocarcinomas | Metastatic Solid Tumors Characterized by HER2/Neu ExpressionUnited States
-
Filipa Lynce, MDAstraZeneca; Daiichi Sankyo, Inc.RecruitingBreast Cancer | HER2-positive Breast Cancer | Invasive Breast Cancer | Inflammatory Breast Cancer Stage III | HER2 Low Breast AdenocarcinomaUnited States
-
Henan Cancer HospitalNot yet recruitingAdvanced Breast Cancer | Treatment | HR Low/HER2 Negative
-
Merck Sharp & Dohme LLCCompletedCancers Expressing HER-2 and/or CEA
-
Bristol-Myers SquibbCompletedHER2 or EGFR Expressing Advanced Solid MalignanciesSpain, France
-
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityJiangsu HengRui Medicine Co., Ltd.RecruitingEarly-stage Breast Cancer | Breast Cancer Invasive | HER2 Low Breast Carcinoma | Hormone-receptor-positive Breast CancerChina
-
GeneQuantum Healthcare (Suzhou) Co., Ltd.RecruitingHER2 Expressing or Mutated Advanced Malignant Solid TumorsChina
-
Masonic Cancer Center, University of MinnesotaActive, not recruitingTriple Negative Breast Cancer | HER2-positive Breast Cancer | TN ER-/PR-/HER2- Breast Cancer | ERany/PRany/HER2+ Breast CancerUnited States
-
Memorial Sloan Kettering Cancer CenterNational Institutes of Health (NIH)RecruitingHER2-positive Metastatic Breast Cancer | HER-2 Protein Overexpression | HER-2 Positive Malignant Carcinoma of BreastUnited States
-
Cancer Trials IrelandCompletedBreast Cancer | HER2 Positive Breast Cancer | HER2 Negative Breast CancerIreland
-
Henan Cancer HospitalRecruitingHER2 Low Breast CarcinomaChina
-
AIO-Studien-gGmbHNovartis Pharmaceuticals; iOMEDICO AGCompletedHer2-negative Metastatic Breast Cancer | Her2-negative Locally Advanced Breast CancerGermany
-
MacroGenicsApproved for marketingHER2-positive Breast Cancer | HER2-positive Carcinoma
-
Hoffmann-La RocheCompletedHER2-Positive Metastatic Breast Cancer | HER2-Negative Metastatic Breast Cancer | Locally Advanced or Early Breast CancerUnited States
-
Mahdis BayatCompletedHER2 Low Breast Carcinoma
-
Bellicum PharmaceuticalsSuspendedHER2-positive Breast Cancer | HER2-positive Gastric Cancer | Solid Tumor, Adult | HER-2 Gene Amplification | HER-2 Protein OverexpressionUnited States
-
H. Lee Moffitt Cancer Center and Research InstituteUnited States Department of DefenseActive, not recruitingBreast Cancer | Breast Cancer, Male | HER2-positive Breast Cancer | Invasive Breast Cancer | Stage II Breast Cancer | Breast Cancer Female | HER2 Positive Breast Carcinoma | Stage III Breast CancerUnited States
-
AstraZenecaCompletedAdvanced Solid Malignancies | Breast Cancer - ER+, HER2 - | Breast Cancer - ER+, HER2-, PIK3CA Gene MutationUnited States, United Kingdom
-
National Cancer Institute (NCI)CompletedHER2-positive Breast Cancer | Stage IV Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast Cancer | HER2-negative Breast CancerUnited States
-
University of ArizonaPfizerCompletedBreast Cancer | Metastatic Breast Cancer | HER2-positive Breast Cancer | Recurrent Breast Cancer | HER2 Positive Breast Carcinoma | Breast Cancer StageUnited States
-
Laura Huppert, MD, BAAmbrx, Inc.Not yet recruitingARX788 for Treating Patients With HER2-low Locally Advanced Unresectable or Metastatic Breast CancerTriple Negative Breast Cancer | Hormone Receptor Positive Breast Carcinoma | HER2 Low Breast Carcinoma | Hormone-receptor-positive Breast CancerUnited States
-
Spanish Breast Cancer Research GroupSeagen Inc.RecruitingHER2-positive Metastatic Breast Cancer | Locally Advanced HER2 Positive Breast CarcinomaSpain
-
Nantes University HospitalInstitut National de la Santé Et de la Recherche Médicale, France; Gilead SciencesCompletedHER2 Negative Breast Carcinoma Expressing CEAFrance